In July 2020, Missoula-based biotech therapeutics company Inimmune announced the largest Series A investment in Montana history: a $22 million round led by Two Bear Capital out of Whitefish.
Two Bear Capital is led by Mike Goguen, a 20-year veteran of Sequoia Capital and based in Whitefish, MT. Goguen commented “The team at Inimmune combines world-class immunology and vaccine expertise, proven track records and a passion for solving some of the most important medical crises of our time.”
Investing in biotechnology helps save lives. Diversify your assets by investing in one our private placements offered through Two Bear Capital. Click Invest With Us to learn more.
For Missoula’s Inimmune, a $22 M Series A Round with Two Bear Capital is the latest record set
The biotech lab partners with UM to address COVID-19, eyes clinical trials
TLR-7/8 (INI-4001), TLR-4 (INI-2002), CTLR (UM-1098), STING
Inimmune is advancing a novel TLR7/8 agonist nanoparticle formulation to the clinic to treat cancer by harnessing the patient’s immune system and synergizing with existing immune checkpoint inhibitor therapies. Further, we’re leveraging our expertise in innate immune activation to develop novel compounds and technology to target other immune receptors to develop the next generation of disruptive therapies in oncology.
Professional doctor or nurse giving flu or COVID-19 injection to patient. Woman in medical face mask getting antiviral vaccine at hospital or health center during vaccination and immunization campaign.